ADC	antibody–drug conjugate
ADCC	antibody-dependent cellular cytotoxicity
ADP	antibody-dependent phagocytosis
APC	antigen-presenting cell
BCMA	B-cell maturation antigen
belamaf	belantamab mafodotin
BiAb	bispecific antibody
BiTE	bispecific T-cell engager
CDC	complement-dependent cytotoxicity
CRS	cytokine release syndrome
CTLA-4	cytotoxic T-lymphocyte antigen 4
d, dex	dexamethasone
Dara	daratumumab
di-scFv	bivalent single-chain variable fragment
Elo	elotuzumab
EMA	European Medicines Agency
Fab	fragment antigen binding
Fc	fragment crystallizable region
FDA	US Food and Drug Administration
G	grade
Ig	immunoglobulin
IMiDs	immunomodulatory drugs
IRR	infusion-related reaction
Isa	isatuximab
iv	intravenous
K	carfilzomib
mAb	monoclonal antibody
MAC	membrane attack complex
MDSC	myeloid-derived suppressor cell
MM	multiple myeloma
MMAF	monomethyl auristatin F
MRD	minimal residual disease
NA	not available
NDMM	in newly diagnosed (ND) MM
NK	natural killer cell
NR	not reached
NTE	non-transplant-eligible
ORR	overall response rate
OS	overall survival
P, Poma	pomalidomide
PD-1	programmed cell death protein 1
PD-L1	programmed death ligand 1
PFS	progression-free survival
PI	proteasome inhibitor
R	lenalidomide
RRMM	relapsed/refractory multiple myeloma
sc	subcutaneous
scFv	single-chain variable fragment
sCR	stringent complete response
SLAMF7	signaling lymphocytic activation molecule family 7
T	thalidomide
TE	transplant-eligible
Treg	regulatory T cell
V	bortezomib
VMP	bortezomib-melphalan-prednisone